Mineralocorticoid receptor antagonists and anti-diabetic agents like semaglutide and SGLT-2 inhibitors hold promise as useful adjunct agents for obese-T2D-HFpEF and should be studied in randomized clinical trials. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.